This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

DosingDosingIBRANCE® Dosing
 
Monitoring RequirementsSafetySafetyIBRANCE® Safety ProfileNeutropeniaAdverse Event ManagementClinical Trials
Clinical TrialsIBRANCE® Clinical TrialsIBRANCE® PALOMA-2 Trial
 
IBRANCE® PALOMA-3 TrialReal World EvidenceReal World EvidenceIBRANCE® Real World EvidenceIRIS (UK) StudyROIS
 
P-REALITY XPatient ProfilesThe Ibrance® PatientPatient ProfilesAlison - >65 years with comorbiditiesBecky - Postmenopausal with bone-only diseaseELEVATE TVSupport and ResourcesSupport and ResourcesIBRANCE Service SupportMaterials
 
Videos

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for the UK. IBRANCE® (palbociclib) Prescribing Information for the UK click here.  Adverse event reporting information can be found at the bottom of the page.

IBRANCE® Dispense and Delivery Service

The IBRANCE® Dispense and Delivery Service provides home delivery to registered patients:

  • Offered to all eligible new or existing stable* on medicine patients considered appropriate by the HCP
  • Patients must be treated in accordance with the SmPC1
  • This service is funded by Pfizer Ltd, the manufacturer of IBRANCE® (palbociclib) and is provided by Alcura on behalf of Pfizer Ltd.
* Stable patients are regarded as those who experience a maximum of Grade 1 or 2 neutropenia in the first six cycles. For these patients, FBC for subsequent cycles should be monitored every 3 months, prior to the beginning of a cycle and as clinically indicated.1

Please click on the video for an illustration of the IBRANCE® Dispense and Delivery Service. This is a video that gives an overall introduction to what the service offering is to NHS Trusts and how it works.

This is a video for those NHS Trusts actively exploring the IBRANCE® Dispense and Delivery Service and wanting further clarity on logistics. This video contains testimonies from existing NHS Trusts and how they set up and implemented the free delivery scheme

Scope

The dispense and delivery service covers:

  • Delivery to the patients home, workplace or a friend or relative
  • Telephone and email support for enrolled patients
  • Monitoring of a patient’s drug supply
  • Delivery arranged using phone or online booking
  • All available strengths/ formulations of the medicine
DeliveryDeliveries will be dispensed by the Alcura pharmacy and delivered by a dedicated national courier.Standard delivery
Monday to Friday: 8:00 am – 6:00 pm
Saturday: 8:00 am – 12:00 pmExtended delivery
Tuesday to Saturday: 9:00 am – 9:00 pmUrgent deliveries
Next day when requiredSame day delivery in urgent or emergency situations
Patients have access to a telephone line and email for delivery queriesPlease contact your local Pfizer Healthcare Partnership Manager for more details

References

IBRANCE® Summary of Product Characteristics for the UK click here. 
PP-IBR-GBR-6257. May 2025

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2025 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-11245. January 2025
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-GBR-12070. April 2025​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024.

YesNo
You are now leaving PfizerPro

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer's medicines or business which it has provided or reviewed.

PP-UNP-GBR-12107. April 2025
​​​​​​​